Due to the largely inadequate efficacy and unreliable safety profiles of TNF inhibitors, several groups are currently conducting research on alternative approaches to biologic-mediated pulmonary sarcoidosis treatment. The gene discussed is TNF; the disease is pulmonary sarcoidosis.